Univest Corp of Pennsylvania lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.2% during the second quarter, Holdings Channel reports. The institutional investor owned 88,880 shares of the company’s stock after selling 1,119 shares during the period. Johnson & Johnson accounts for approximately 4.9% of Univest Corp of Pennsylvania’s investment portfolio, making the stock its 2nd largest position. Univest Corp of Pennsylvania’s holdings in Johnson & Johnson were worth $10,781,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Americafirst Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter worth $101,000. Capital Asset Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth about $202,000. Terra Nova Asset Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth about $243,000. Daiwa SB Investments Ltd. increased its position in shares of Johnson & Johnson by 8.4% in the second quarter. Daiwa SB Investments Ltd. now owns 2,970 shares of the company’s stock worth $354,000 after buying an additional 230 shares during the last quarter. Finally, Pure Financial Advisors Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth about $355,000. Institutional investors own 65.32% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded up 0.25% during mid-day trading on Thursday, reaching $118.26. 7,387,365 shares of the company’s stock were exchanged. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The stock has a market capitalization of $323.54 billion, a PE ratio of 22.04 and a beta of 0.62. The firm’s 50-day moving average is $118.77 and its 200 day moving average is $117.29.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on JNJ. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.14 price target on the stock in a research report on Monday, October 3rd. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 28th. Credit Suisse Group AG reaffirmed a “neutral” rating and set a $123.00 price target on shares of Johnson & Johnson in a research report on Monday, September 19th. Jefferies Group reduced their price target on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 13th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, September 11th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $120.19.
In other news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.